

TECHNICAL SPECIFICATION

ISO/TS
19844

Third edition
2018-07

Health informatics — Identification of medicinal products (IDMP) — Implementation guidelines for ISO 11238 for data elements and structures for the unique identification and exchange of

iTeh ST_READYVIEW on substances
(standards.iteh.ai)

Informatique de santé — Identification des médicaments — Lignes directrices pour la mise en œuvre de l'ISO 11238 relative aux éléments de données et structures pour l'identification unique et l'échange d'informations réglementées sur les substances ISO/TS 19844:2018
<https://standards.iteh.ai/iso/iso-11238-2018>



Reference number
ISO/TS 19844:2018(E)

iTeh STANDARD PREVIEW (standards.iteh.ai)

[ISO/TS 19844:2018](#)

<https://standards.iteh.ai/catalog/standards/sist/feca95ea-ef26-4628-bbeb-255e62bc1c0c/iso-ts-19844-2018>



COPYRIGHT PROTECTED DOCUMENT

© ISO 2018

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Fax: +41 22 749 09 47
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Contents

Foreword.....	viii
Introduction.....	ix
1 Scope	1
2 Normative references	2
3 Symbols and abbreviated terms.....	2
4 General background and history	5
5 Substance (Mandatory)	7
5.1 General	7
5.2 Defining substances.....	9
5.2.1 Substance type (Mandatory)	10
5.2.2 Substance ID (Mandatory).....	14
5.3 Substance names (Mandatory)	15
5.3.1 Substance name (Mandatory)	16
5.3.2 Substance name type (Mandatory)	17
5.3.3 Language (Mandatory)	17
5.3.4 Substance name domain (Conditional)	18
5.3.5 Jurisdiction (Conditional).....	18
5.3.6 Official name (Conditional).....	19
5.4 Reference source (Conditional).....	20
5.4.1 Public domain (Conditional).....	20
5.4.2 Reference source type (Mandatory)	21
5.4.3 Reference source class (Optional).....	21
5.4.4 Reference source ID (Conditional).....	22
5.4.5 Reference source citation (Conditional).....	22
5.4.6 Reference source URL (Conditional)	22
5.4.7 Reference source document (Conditional)	22
5.5 Substance code (Conditional)	24
5.5.1 Code (Mandatory).....	24
5.5.2 Code system (Mandatory).....	25
5.5.3 Code system ID (Mandatory)	25
5.5.4 Code system status (Mandatory)	25
5.5.5 Code change date (Optional)	26
5.5.6 Comment (Optional).....	26
5.5.7 Reference source (Conditional).....	26
5.6 Reference information (Conditional).....	26
5.6.1 Comment (Optional)	27
5.6.2 Substance classification (Conditional)	27
5.6.3 Substance relationship (Conditional)	30
5.6.4 Target (Conditional)	32
5.6.5 Gene (Conditional)	34
5.6.6 Gene element (Conditional).....	35
5.7 Structure (Conditional)	36
5.7.1 Stereochemistry (Conditional)	37
5.7.2 Optical activity (Conditional)	37
5.7.3 Molecular Formula (Conditional)	38
5.7.4 Molecular Formula by Moiety (Conditional)	38
5.7.5 Molecular weight (Mandatory).....	38
5.7.6 Structural Representation (Conditional).....	38

5.7.7	Isotope (Conditional)	43
5.7.8	Reference Source (Conditional)	45
5.8	Amount (Conditional)	45
5.8.1	Amount type (Conditional)	45
5.8.2	Quantity (Conditional)	45
5.8.3	Low limit (Conditional)	45
5.8.4	High limit (Conditional)	46
5.8.5	Unit (Conditional)	46
5.8.6	Non-numeric Value (Conditional)	46
5.8.7	Amount text (Conditional)	47
5.8.8	Reference range (Conditional)	47
5.9	Source material (Conditional)	47
5.9.1	Source material class (Conditional)	48
5.9.2	Source material type (Conditional)	49
5.9.3	Source material state (Conditional)	49
5.9.4	Organism ID (Conditional)	49
5.9.5	Organism name (Conditional)	49
5.9.6	Parent substance ID (Conditional)	50
5.9.7	Parent substance name (Conditional)	50
5.9.8	Country of origin (Conditional)	50
5.9.9	Geographical location (Conditional)	50
5.9.10	Development stage (Conditional)	51
5.9.11	Part Description (Conditional)	51
5.9.12	Fraction description (Conditional)	52
5.9.13	Organism (Conditional)	52
5.10	Modification (Conditional)	57
5.10.1	Modification type (Conditional)	59
5.10.2	Residue modified (Conditional)	59
5.10.3	Residue site (Conditional)	60
5.10.4	Structural modification (Conditional)	60
5.10.5	Agent modification (Conditional)	62
5.10.6	Physical Modification (Conditional)	63
5.11	Property (Conditional)	64
5.11.1	Property type (Conditional)	65
5.11.2	Property name (Conditional)	65
5.11.3	Property parameters (Conditional)	65
5.11.4	Property substance ID (Conditional)	66
5.11.5	Property substance name (Conditional)	66
5.11.6	Amount (Mandatory)	66
5.12	Version (Mandatory)	66
5.12.1	Version number (Mandatory)	67
5.12.2	Effective date (Mandatory)	67
5.12.3	Change made (Conditional)	67
6	Substance definitions	67
6.1	Chemical substance	68
6.1.1	Structure (Mandatory)	69
6.1.2	Stoichiometric/Non-stoichiometric chemicals	69
6.1.3	Stoichiometric (Mandatory)	72
6.1.4	Number of moieties (Conditional)	72
6.1.5	Comment (Optional)	72
6.1.6	Moiety (Conditional)	72
6.1.7	Property (Conditional)	75
6.1.8	Substance Name (Mandatory)	75

6.1.9	Substance Code (Conditional)	75
6.1.10	Version (Mandatory)	76
6.1.11	Reference information (Conditional)	76
6.1.12	Reference source (Conditional)	76
6.2	Proteins/peptides	76
6.2.1	Microheterogeneity	77
6.2.2	Sequence type (Mandatory)	77
6.2.3	Number of subunits (Mandatory)	78
6.2.4	Disulfide linkage (Conditional)	78
6.2.5	Comment (Optional)	78
6.2.6	Protein subunit (Mandatory)	78
6.2.7	Molecular weight (Conditional)	81
6.2.8	Glycosylation (Conditional)	82
6.2.9	Property (Conditional)	83
6.2.10	Structure (Conditional)	84
6.2.11	Substance name (Mandatory)	84
6.2.12	Modification (Conditional)	84
6.2.13	Substance code (Conditional)	84
6.2.14	Source material (Conditional)	84
6.2.15	Version (Mandatory)	84
6.2.16	Reference information (Conditional)	84
6.2.17	Reference source (Conditional)	84
6.3	Nucleic acids	84
6.3.1	Structure (Conditional)	85
6.3.2	Sequence type (Mandatory)	86
6.3.3	Number of subunits (Mandatory)	86
6.3.4	Area of hybridization (Conditional)	87
6.3.5	Oligo nucleotide type (Conditional)	87
6.3.6	Comment (Optional)	87
6.3.7	Nucleic acid subunit (Mandatory)	87
6.3.8	Modification (Conditional)	91
6.3.9	Property (Conditional)	91
6.3.10	Molecular weight (Conditional)	92
6.3.11	Substance Name (Mandatory)	92
6.3.12	Substance Code (Conditional)	92
6.3.13	Version (Mandatory)	92
6.3.14	Reference information (Conditional)	92
6.3.15	Reference source (Conditional)	92
6.4	Polymers	92
6.4.1	Polymer class (Mandatory)	93
6.4.2	Polymer geometry (Mandatory)	94
6.4.3	Copolymer connectivity (Mandatory)	94
6.4.4	Comment (Optional)	94
6.4.5	Substance name (Mandatory)	94
6.4.6	Structure (Mandatory)	94
6.4.7	Monomer set description (Conditional)	95
6.4.8	Structural repeat (Mandatory)	96
6.4.9	Molecular weight (Conditional)	99
6.4.10	Property (Conditional)	100
6.4.11	Substance code (Conditional)	100
6.4.12	Version (Mandatory)	100
6.4.13	Reference information (Conditional)	100
6.4.14	Modification (Conditional)	100

6.4.15	Source material (Conditional)	100
6.4.16	Reference source (Conditional)	100
6.5	Structurally diverse substances.....	100
6.5.1	Comment (Optional)	101
6.5.2	Substance name (Mandatory).....	101
6.5.3	Structure (Conditional).....	102
6.5.4	Property (Conditional).....	102
6.5.5	Molecular weight (Conditional)	102
6.5.6	SD glycosylation (Conditional)	102
6.5.7	Modification (Conditional)	102
6.5.8	Source material (Mandatory)	102
6.5.9	Substance code (Conditional)	102
6.5.10	Reference information (Conditional)	102
6.5.11	Version (Mandatory)	102
6.5.12	Reference source (Conditional)	103
6.5.13	Herbals and substances used in the preparation of plant-based allergenic extracts	103
6.5.14	Vaccines	105
6.5.15	Plasma-derived substance for human blood products and polyclonal antibodies..	105
6.5.16	Allergens.....	105
6.5.17	Advanced Therapies and Advanced Vaccines (Genes, Modified Viruses, Cells and Tissues as Substances)	105
6.5.18	Minerals.....	106
6.6	Mixture.....	106
6.6.1	Mixture type (Mandatory)	107
6.6.2	Is multi-substance starting material (Mandatory)	107
6.6.3	Constituent component (Mandatory)	108
6.6.4	Multi-substance starting material property (Conditional) <small>ISO/TS 19844-2018 https://standards.iteh.ai/catalog/standards/sist/teca95ca-el26-4628-bbeb-255e62bc1c0c/iso-ts-19844-2018</small>	109
6.6.5	Modification (Conditional)	109
6.6.6	Source material (Conditional)	110
6.6.7	Substance name (Mandatory).....	110
6.6.8	Substance code (Conditional)	110
6.6.9	Reference information (Conditional)	110
6.6.10	Version (Mandatory)	110
7	Specified substance (Conditional)	110
7.1	Specified Substance Group 1 (Conditional)	110
7.1.1	Specified substance Group 1 ID (Mandatory)	111
7.1.2	Substance name (Mandatory).....	111
7.1.3	Substance Code (Conditional).....	112
7.1.4	Version (Mandatory)	112
7.1.5	Reference source (Conditional)	112
7.1.6	Constituent (Conditional)	112
7.1.7	Characteristic attribute (Conditional).....	114
7.1.8	Fraction description (Conditional)	117
7.1.9	Modification (Conditional)	118
7.1.10	Reference Information (Conditional)	118
7.1.11	Physical form (Conditional)	118
7.2	Specified substance Group 2 (Conditional)	119
7.2.1	Specified Substance Group 2 ID (Mandatory)	121
7.2.2	Substance Name (Mandatory)	121
7.2.3	Substance code (Conditional)	121
7.2.4	Reference source (Conditional)	121
7.2.5	Reference information (Conditional)	121

7.2.6	Version (Mandatory)	121
7.2.7	Manufacturing (Mandatory)	121
7.3	Specified Substance Group 2 Extended (Conditional).....	126
7.3.1	Specified Substance Group 2 ID (Mandatory)	126
7.3.2	Substance Name (Mandatory)	126
7.3.3	Substance code (Conditional)	126
7.3.4	Reference source (Conditional).....	126
7.3.5	Reference information (Conditional).....	126
7.3.6	Version (Mandatory)	126
7.3.7	Manufacturing (Mandatory)	127
7.4	Specified Substance Group 3 (Conditional).....	131
7.4.1	Specified Substance Group 3 ID (Mandatory)	131
7.4.2	Substance Name (Mandatory)	132
7.4.3	Grade (Mandatory)	132
7.4.4	Version (Mandatory)	132
7.4.5	Substance code (Conditional)	132
7.4.6	Reference information (Conditional).....	133
7.4.7	Reference source (Conditional).....	133
8	Description of the information modelling principles and practices.....	133
8.1	General considerations	133
8.2	Conceptual overview diagrams	133
8.3	Section high-level diagrams.....	134
8.4	Detailed diagrams	134
8.4.1	Relationships between classes	135
8.4.2	Notes.....	136
8.4.3	Attributes.....	137
8.4.4	Message exchange format.....	137
8.4.5	Conformance terminology and context as it relates to the ISO 11238 and ISO/TS 19844 exchange format.....	138
	Annex A (informative) Choosing a Substance ID	139
	Annex B (informative) Chemical substance	141
	Annex C (normative) Protein substance.....	251
	Annex D (informative) Nucleic acid substance	324
	Annex E (normative) Structurally Diverse Substance — Herbal Substance/Herbal Specified Substance.....	346
	Annex F (informative) Structurally Diverse Substance, Homeopathic substance	482
	Annex G (informative) Structurally Diverse Substance — Plasma-derived substances....	526
	Annex H (normative) Polymer Substance.....	592
	Annex I (informative) Structurally Diverse, Vaccines.....	636
	Annex J (informative) Structurally Diverse, Allergen Substances	796
	Annex K (informative) Advanced Therapies and Advanced Vaccines (Genes, Modified Viruses, Cells and Tissues as Substances) (Placeholder)	871
	Bibliography	877

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

**iTeh STANDARD PREVIEW
(standards.iteh.ai)**
For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the WTO principles in the Technical Barriers to Trade (TBT) see the following URL: [Foreword - Supplementary information](#)

[ISO/TS 19844:2018](#)

The committee responsible for this document is ISO/TC 215, *Health informatics*.
<https://standards.iteh.ai/catalog/standards/sist/feca95ea-ef26-4628-bbeb-233e62bc1e0c/iso-ts-19844-2018>

This third edition cancels and replaces the second edition (ISO/TS 19844:2016), which has been technically revised.

Introduction

This document provides guidelines for implementing ISO 11238. This document is developed in response to a worldwide demand for guidance on the implementation of internationally harmonized specifications for medicinal products. It is one of a group of four implementation guides for a total of five ISO standards which together provide the basis for the unique identification of medicinal products. The other standards in this group are:

- ISO 11615, *Health informatics — Identification of medicinal products — Data elements and structures for the unique identification and exchange of regulated medicinal product information*;
- ISO 11616, *Health informatics — Identification of medicinal products — Data elements and structures for the unique identification and exchange of regulated pharmaceutical product information*;
- ISO 11239^[2], *Health informatics — Identification of medicinal products — Data elements and structures for the unique identification and exchange of regulated information on pharmaceutical dose forms, units of presentation, routes of administration and packaging*;
- ISO 11240, *Health informatics — Identification of medicinal products — Data elements and structures for the unique identification and exchange of units of measurement*.

The standards for the Identification of Medicinal Products (IDMP) support the activities of medicines regulatory agencies worldwide by jurisdiction. These include a variety of regulatory activities related to development, registration and life cycle management of medicinal products as well as pharmacovigilance and risk management.

The business objective of this implementation guide is to provide a means for exchanging regulatory substance information. To meet the primary objectives of the regulation of medicines and pharmacovigilance, it is necessary to exchange medicinal product information in a robust and reliable manner.

For the purposes of this document, all conditions (e.g. mandatory, conditional, optional) correspond to the necessary requirements to uniquely and unambiguously identify a substance. Implementation of the ISO IDMP standards may dictate that mandatory elements for identification be tagged as conditional or optional, based on regional requirements. If a subclause is identified as ‘optional’ but is implemented in a specific region, conformance described within that subclause is applicable. The scope of this document is to identify the scientifically necessary elements for the unique identification of Substances/Specified Substances.

In this document, “% {v/v}” is used in place of “% volume fraction”.

iTeh STANDARD PREVIEW

(standards.iteh.ai)

ISO/TS 19844:2018

<https://standards.iteh.ai/catalog/standards/sist/feca95ea-ef26-4628-bbeb-255e62bc1c0c/iso-ts-19844-2018>

Health informatics — Identification of medicinal products (IDMP) — Implementation guidelines for ISO 11238 for data elements and structures for the unique identification and exchange of regulated information on substances

CAUTION — This document uses colour. This should be taken into consideration when printing.

1 Scope

This document is used in the implementation of ISO 11238. This document defines substances based on their scientific identity (i.e. what they are) rather than on their use or method of production.

ISO 11238 provides the conceptual framework for defining Substances and Specified Substances and for assigning unique identifiers in the context of the ISO IDMP standards. ISO 11238 describes general concepts for defining and distinguishing substances and a high-level model for the structuring of information for substances. This document provides detailed explanations of each type or grouping of substance information, an element-by-element description for implementation of ISO 11238, and examples for a variety of Substances and Specified Substances.

This third edition of the document addresses Substances Groups 1 to 3 of the Specified Substances as defined in ISO 11238 and Annexes A, B, C, D, E, F, G, H, I, J and K. It is anticipated that Specified Substances Group 4, as defined in ISO 11238, will be addressed in a subsequent edition of this document. Some information that would typically fall under Specified Substances Group 4 is covered in the Annexes of this document. This information, although not defining either a Substance or a Specified Substance Group 1, might be essential to distinguishing substances. This document addresses the following:

- data elements necessary for defining Substances and Specified Substances Groups 1 to 3;
- the logical use of data elements as defined in ISO 11238;
- Substances and Specified Substances Groups 1 to 3 business rules for:
 - determining necessary data elements,
 - distinguishing and defining materials according to ISO 11238,
 - triggering the assignment of identifiers.

This document does not address the following:

- business processes for data management;
- implementation of a specific data information system (e.g. a relational database schema);
- normative messaging standards for substances;
- the maintenance of controlled vocabularies;
- the specific global identifier system that should be used;

- nomenclature standards for substances.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 639-1, *Codes for the representation of names of languages — Part 1: Alpha-2 code*

ISO 3166-1:2013, *Codes for the representation of names of countries and their subdivisions — Part 1: Country codes*

ISO 8601, *Data elements and interchange formats — Information interchange — Representation of dates and times*

ISO 11238, *Health informatics — Identification of medicinal products — Data elements and structures for the unique identification and exchange of regulated information on substances*

ISO 11240, *Health informatics — Identification of Medicinal Products — Data elements and structures for the unique identification and exchange of units of measurement*

ISO 11615, *Health informatics — Identification of Medicinal Products — Data elements and structures for the unique identification and exchange of regulated Medicinal Product information*

The STANDARD PREVIEW

ISO 11616, *Health informatics — Identification of Medicinal Products — Data elements and structures for the unique identification and exchange of regulated pharmaceutical product information*

ISO/TS 20443, *Health informatics — Identification of Medicinal Products — Implementation guide for ISO 11615 data elements and structures for the unique identification and exchange of regulated Medicinal Product information*
https://standards.iec.ch/catalog/standards/iso/fora/95ca-p06_4628.html
255e62bc1c0c/iso-ts-19844-2018

ISO/TS 20451, *Health informatics — Identification of Medicinal Products — Implementation guide for ISO 11616 data elements and structures for the unique identification and exchange of regulated pharmaceutical product information*

3 Terms and definitions

No terms and definitions are listed in this document.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <https://www.iso.org/obp>
- IEC Electropedia: available at <http://www.electropedia.org/>

4 Symbols and abbreviated terms

NOTE The abbreviations are listed are either used within ISO 11238 or ISO/TS 19844 since they are regarded as inseparable documents.

4.1**ACS**American Chemical Society¹**4.2****ASK Number**

ID of a substance in German “Arzneistoffkatalog” (Pharmaceutical Substance Dictionary)

4.3**BAN**British Approved Name^[127]**4.4****COL**Catalogue of Life²**4.5****DCF**Dénominations Communes Françaises (French approved drug name)^[128]**4.6****EVcode**EudraVigilance Code (Unique Identifier) used for a substance in the Extended EudraVigilance Medicinal Product Dictionary (XEVMPD)³**STANDARD PREVIEW
(standards.iteh.ai)****4.7****ExPASy**SIB (Swiss Institute of Bioinformatics) Bioinformatics Resource Portal⁴<https://standards.iteh.ai/catalog/standards/sist/feca95ea-ef26-4628-bbeb-255e62bc1c0c/iso-ts-19844-2018>**4.8****HAB**

Homöopathisches Arzneibuch, Amtliche Ausgabe

4.9**HTS**

high-throughput sequencing

4.10**INCI**International Nomenclature of Cosmetic Ingredients⁵¹ <https://www.acs.org/content/acs/en.html>² <http://www.catalogueoflife.org/>³ http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000596.jsp⁴ <https://www.expasy.org/>⁵ http://www.cirs-reach.com/Cosmetic_Inventory/International_Nomenclature_of_Cosmetic_Ingredients_INCI.html

4.11

INN

International Nonproprietary Name [also consider as rINN (recommended International Nonproprietary Name) or pINN (proposed International Nonproprietary Name)]⁶

4.12

iPSCs

induced pluripotent stem cells

4.13

ITIS

Integrated Taxonomic Information System⁷

4.14

JAN

Japanese Approved Name⁸

4.15

JP

Japanese Pharmacopoeia^[129]

4.16

NCBI

National Center for Biotechnology Information

**iTEH STANDARD PREVIEW
(standards.iteh.ai)**

4.17

NDF-RT

National Drug File - Reference Terminology, ISO/TS 19844-2018 produced by the U.S. Department of Veterans Affairs, Veterans Health Administration (VHA)^[130] <https://www.ncbi.nlm.nih.gov/catalog/standards/sist/feca95ea-ef26-4628-bbeb-255e62bc1c0c/iso-ts-19844-2018>

4.18

NLT

not less than

4.19

NMT

not more than

4.20

OMG

Object Management Group⁹

4.21

PBMCs

Peripheral Blood Mononuclear cells

⁶ <http://www.who.int/medicines/services/inn/en/>

⁷ <https://www.itis.gov/>

⁸ <http://jpdb.nih.go.jp/jan/index.aspx>

⁹ <http://www.omg.org/>

4.22**Ph.Eur.**

European Pharmacopoeia (Pharmacopée Européenne)^[131]

4.23**UCUM**

Unified Code for Units of Measure¹⁰

4.24**UML**

Unified Modeling Language¹¹

4.25**UNII**

Unique Ingredient Identifier. Identifier of a substance in the FDA Global Substance Registration System (G-SRS)¹²

4.26**UniProt**

Universal Protein Resource¹³

4.27**USAN**

United States Adopted Name¹⁴ **iTeH STANDARD PREVIEW**

(standards.iteh.ai)

4.28**USP**

United States Pharmacopeia^[132]

[ISO/TS 19844:2018](#)

<https://standards.iteh.ai/catalog/standards/sist/feca95ea-ef26-4628-bbeb-255e62bc1c0c/iso-ts-19844-2018>

4.29**WHO-ATC**

World Health Organization – Anatomical Therapeutic Chemical Classification System^[133]

5 General background and history

Due to the lack of a common and harmonized approach to define substances, regulators and pharmaceutical industry are faced with the inability to:

- 1) effectively exchange medicinal substance information in a structured and efficient way;
- 2) ensure data consistency and evaluate/compare information across regions, which especially impairs pharmacovigilance and compliance activities;
- 3) develop consistent terminology for use throughout the healthcare community.

¹⁰ <http://unitsofmeasure.org/trac>

¹¹ <http://www.uml.org/>

¹² <https://www.fda.gov/forindustry/datastandards/substanceregistrationsystem-uniqueingredientidentifierunii/>

¹³ <http://www.uniprot.org/>

¹⁴ <https://www.ama-assn.org/about/united-states-adopted-names-council>